Welcome to the Lee laboratory. Our aim is to identify molecular drivers and biological properties of prostate and bladder cancer that may be exploited for the development of new and effective treatments. In our research we employ cutting-edge technologies including mouse and human epithelial transformation systems; functional genomics; multi-omic data integration; high-throughput screening; small molecule drug discovery; and immuno-oncology to develop new approaches to stratify and treat prostate and bladder cancer.
Combinatorial genetic strategy accelerates the discovery of cancer genotype-phenotype associations. Li S, Wong A, Sun H, Bhatia V, Javier G, Jana S, Montgomery RB, Wright JL, Lam H-M, Hsieh AC, Faltas BM, Haffner MC, Lee JK.
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Bhatia V, Kamat NV, Pariva TE, Wu L, Tsao A, Sasaki K, Sun H, Javier G, Nutt S, Coleman I, Hitchcock L, Zhang A, Rudoy D, Gulati R, Patel RA, Roudier MP, True LD, Srivastava S, Morrissey CM, Haffner MC, Nelson PS, Priceman SJ, Ishihara J, Lee JK.
Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. DeLucia DC, Cardillo TM, Ang LS, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, Gil da Costa RM, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK.
Gerardo Javier Sanchez joins the lab as a permanent graduate student enrolled in the UW M3D graduate program. Welcome!
The Lee Lab is awarded a Bladder Cancer Advocacy Network (BCAN) 2021 Bladder Cancer Research Innovation Award to support research on understanding determinants of variant histologies of bladder cancer initiation/maintenance and their response to chemoimmunotherapy.
Vipul Bhatia joins the lab as a post-doctoral fellow. Welcome!